Hsbc Global Res Upgrades Qiagen (NYSE:QGEN) to “Hold”

Qiagen (NYSE:QGEN) was upgraded by research analysts at Hsbc Global Res to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

QGEN has been the subject of several other research reports. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research note on Thursday. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research note on Thursday, June 27th. Finally, Robert W. Baird boosted their price objective on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Qiagen currently has an average rating of “Moderate Buy” and an average target price of $50.12.

Qiagen Trading Down 1.2 %

Shares of QGEN stock opened at $42.69 on Thursday. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.44. The stock’s fifty day moving average price is $45.14 and its two-hundred day moving average price is $43.51. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The company has a market cap of $9.74 billion, a PE ratio of 142.05, a P/E/G ratio of 3.36 and a beta of 0.39.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.03. The business had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. Qiagen’s revenue was down .2% compared to the same quarter last year. During the same period last year, the firm posted $0.53 earnings per share. Equities analysts predict that Qiagen will post 2.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of QGEN. GAMMA Investing LLC raised its position in shares of Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after acquiring an additional 500 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Qiagen during the 2nd quarter valued at approximately $27,000. Riverview Trust Co bought a new position in Qiagen during the 1st quarter worth approximately $28,000. Park Place Capital Corp acquired a new position in shares of Qiagen in the 1st quarter worth approximately $36,000. Finally, Massmutual Trust Co. FSB ADV boosted its stake in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.